Newsletter February 16th, 2019

Dear Foregen Supporters,

Welcome back to our most recent newsletter. We have some important updates for you, and an overview of the best parts of February so far.

What's Happened Since Last Time

  • As we work with the university on our research and ethics approval, we’ve placed an order for 25 foreskins to be used in animal trials, so we will be prepared for the next phase of research.

 

  • Beginning on April 8th Foregen’s president Vincenzo Aiello will be hosting an exhibit of his new version of HuFo at Open Space Studio in Philadelphia!  All Foregen supporters and anyone interested is invited to come and talk with our founder. The HuFo has proven to be a valuable tool for communicating the importance and meaning of Foregen’s work, so this is an excellent promotion of our research.

 

  • Right now we're in contact with a few different media outlets. We hope that they might take interest in our project given our recent advances and the progress that we’ll be making.

 

  • From March 10-13th Foregen will be hosting a booth at SXSW!  We made valuable connections at the trade show last year and we hope that with our now published research that we can get even more interest this time around.

 

  • For the month of February so far we reached a total of $4,816 in donations, which helps us move forward with the next parts of our mission!  Be sure to inform other activists, friends and family about Foregen and the science we’re pursuing to one day help provide genital integrity to men around the world. Our overall total to date is $417,405 - Let’s keep it up.

 

Tell Me Something Interesting

  • This recently published paper in Nature describes how “In Situ bioprinting of autologous skin cells accelerates wound healing of extensive excisional full-thickness wounds”.  More specifically how “Wounds treated using in-situ skin bioprinting demonstrated faster wound closure compared to untreated and matrix-treated group (Fig. 2B). In the printed group, the wound area at 1 week post-surgery was 66% of the original wound area. In contrast, the wounds in the control groups remained at 95% of their original wound size at the same time point (n = 12, p ≤ 0.001). At 2 weeks, the wounds treated with printed cells were only 15% of the original size, while the wounds in the control groups were 40% of the original size (n = 8, p ≤ 0.05). Overall, printed skin cells were able to close the entire wound by 3 weeks post-surgery compared to 5 weeks for both negative controls.”

 

  • This announcement discusses the “first cell therapy from engineered pluripotent stem cell [to] receive IND[...]  The FDA has approved the Investigational New Drug (IND) application for FT516, a natural killer cell therapy and the first produced from a single genetically engineered pluripotent stem cell to be cleared for clinical testing. FT516, developed by Fate Therapeutics (CA, USA), will be tested for the indications of acute myelogenous leukemia, non-Hodgkin's lymphoma and multiple myeloma.”

 

Volunteer for Foregen

If you are interested in any of the following positions, please click on them to read more and apply:

Foregen Web Developers

Foregen Translators

Thanks for reading, and stay tuned for our next newsletter. If you’d like more frequent updates, please head over to our blog, or visit one of our social media accounts – the links are at the bottom of this newsletter.

Best,

The Foregen Team

Please check your e-mail for a link to activate your account.